The recently developed aluminum-[18F]-labeled 1,4,7-triazacyclononane-N,N′,N′′-triacetic acid-conjugated FAP inhibitor 04 ([18F]AlF-NOTA-FAPI-04) effectively visualizes various primary tumors and quantitatively assesses tumor involvement in cancer patients. This evidence concerns the gene FAP and cancer.